BACKGROUND: The aim of this study was to analyze the survival difference between advanced non-small cell lung cancer (NSCLC) patients in the pre-gefitinib and post-gefitinib eras in Korea. PATIENTS AND METHODS: 830 patients with advanced/metastatic or recurrent NSCLC who received palliative chemotherapy were retrospectively reviewed. Using a matched-pair case-control study design, 334 pairs from the pre-gefitinib era (January 1999 to December 2001) and the post-gefitinib era (January 2002 to December 2005) were matched by age, sex and histology. RESULTS: The median overall survival from the date of first administration of palliative chemotherapy was significantly longer in the post-gefitinib era (11.5 vs. 19.3 months, p< 0.001). Multivariate analysis showed that gefitinib was associated with longer overall survival (hazard ratio 0.58, p< 0.001) as were never having been a smoker, adenocarcinoma histology, good performance, stage IIIB, >or=3 prior episodes of chemotherapy, platinum-based chemotherapy and previous docetaxel or pemetrexed treatment. Patients in the post-gefitinib era showed significantly longer overall survival in almost all subgroups. Gefitinib treatment was of significantly greater benefit in patients with adenocarcinoma than in those with non-adenocarcinoma (test for interaction p< 0.001). CONCLUSION: These results indicate a significant improvement of survival in advanced NSCLC patients treated with gefitinib in Korea. Copyright 2009 S. Karger AG, Basel.
BACKGROUND: The aim of this study was to analyze the survival difference between advanced non-small cell lung cancer (NSCLC) patients in the pre-gefitinib and post-gefitinib eras in Korea. PATIENTS AND METHODS: 830 patients with advanced/metastatic or recurrent NSCLC who received palliative chemotherapy were retrospectively reviewed. Using a matched-pair case-control study design, 334 pairs from the pre-gefitinib era (January 1999 to December 2001) and the post-gefitinib era (January 2002 to December 2005) were matched by age, sex and histology. RESULTS: The median overall survival from the date of first administration of palliative chemotherapy was significantly longer in the post-gefitinib era (11.5 vs. 19.3 months, p< 0.001). Multivariate analysis showed that gefitinib was associated with longer overall survival (hazard ratio 0.58, p< 0.001) as were never having been a smoker, adenocarcinoma histology, good performance, stage IIIB, >or=3 prior episodes of chemotherapy, platinum-based chemotherapy and previous docetaxel or pemetrexed treatment. Patients in the post-gefitinib era showed significantly longer overall survival in almost all subgroups. Gefitinib treatment was of significantly greater benefit in patients with adenocarcinoma than in those with non-adenocarcinoma (test for interaction p< 0.001). CONCLUSION: These results indicate a significant improvement of survival in advanced NSCLCpatients treated with gefitinib in Korea. Copyright 2009 S. Karger AG, Basel.
Authors: William W Lockwood; Raj Chari; Bradley P Coe; Kelsie L Thu; Cathie Garnis; Chad A Malloff; Jennifer Campbell; Ariane C Williams; Dorothy Hwang; Chang-Qi Zhu; Timon P H Buys; John Yee; John C English; Calum Macaulay; Ming-Sound Tsao; Adi F Gazdar; John D Minna; Stephen Lam; Wan L Lam Journal: PLoS Med Date: 2010-07-27 Impact factor: 11.069
Authors: H Schultz; S Marwitz; B Baron-Lühr; G Zissel; C Kugler; K F Rabe; P Zabel; E Vollmer; J Gerdes; T Goldmann Journal: Br J Cancer Date: 2011-08-02 Impact factor: 7.640